GlassScriptPhysician profile
Rachael C Monroe
NPI 1659692754
$2,784.54
in general payments reported to CMS, 2019-2025
37 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $752 · 2021: $316 · 2022: $496 · 2023: $121 · 2024: $166 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.94 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $618.45 | 2019-2025 | Prolia, Repatha, Otezla |
| Pfizer INC. | $254.84 | 2019-2025 | |
| Abbvie INC. | $225.26 | 2019-2025 | |
| Medicure Pharma INC. | $178.96 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $161.93 | 2019-2023 | Farxiga |
| Sumitomo Pharma America, INC. | $121.03 | 2023-2025 | Gemtesa |
| Edwards Lifesciences Corporation | $106.35 | 2019-2022 | |
| Allergan, INC. | $87.47 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.48 | 2019-2021 | |
| Novo Nordisk INC | $79.56 | 2019 | |
| Lilly USA, LLC | $74.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.89 | 2020-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $64.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $59.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $49.71 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $49.59 | 2020 | |
| Glaxosmithkline, LLC. | $46.07 | 2020-2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $43.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.59 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $36.54 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $32.71 | 2023 | Optimizer |
| Amneal Pharmaceuticals LLC | $31.38 | 2022 | |
| Sunovion Pharmaceuticals INC. | $27.30 | 2022 | |
| Astellas Pharma US INC | $26.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.91 | 2019-2021 | |
| Genentech USA, INC. | $23.95 | 2019 | |
| Dermira, INC. | $21.94 | 2020 | |
| Daiichi Sankyo INC. | $16.90 | 2021 | |
| Merck Sharp & Dohme LLC | $16.21 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2021 | |
| Philips North America LLC | $16.04 | 2024 | (Ck6) Holter |
| Nestle Healthcare Nutrition INC. | $15.95 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.48 | 2025 | Uptravi, Opsumit |
| Kowa Pharmaceuticals America, INC. | $15.19 | 2020 | |
| Abbott Laboratories | $12.30 | 2021 | |
| Esperion Therapeutics, INC. | $12.28 | 2020 | |
| Phadia US INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.